Coventry, UK, 5th November 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully compl
5th November 2018
3rd October 2018
Coventry, UK, 3rd October 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medic
11th September 2018
Medherant has been shortlisted for the CPhI Pharma Awards in both the Formulation and Drug Delivery Devices categories for its TEPI Patch® technology.
6th June 2018
Transdermal drug delivery systems have been used in different forms since ancient times.
7th March 2018
Medherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development. This appointment marks a significant expansion of the Company’s management team to support the business as it moves into clinical development of its ibuprofen TEPI Patch®.
14th February 2018
There are many problems linked to oral drug administration including first pass metabolism, gastrointestinal tract damage and low levels of drug reaching the target site.